Hydrix Limited · ASX:HYD
Hydrix — Non-Deal Roadshow (September 2023)
24 slides from Hydrix's roadshow presentation, Sep 25, 2023
Slide 1: ASX announcement: updated investor presentation
Hydrix Limited (ASX:HYD) is pleased to provide its updated investor presentation which recaps the Group’s strategy, incorporates the financial results for the year ending 30 June 2023, and outlines key obejectives for the next twelve months. For personal use only Ends ---- This announcement is autho
Slide 2: Medical technology innovation: Investor Presentation
For personal use only Medical technology innovation ASX : HYD Investor Presentation Non-deal Roadshow September 2023
Slide 3: About us: we create, invest in, and deliver innovation
For personal use only About us: We create, invest in, and deliver the innovation in breakthrough technologies…. Top: Artificial Heart (TAH) under development by Scandinavian Realheart Bottom: TAH controller under development by Hydrix 2 |
Slide 4: Our 'buy, build, invest' strategy to sustained profitable growth
For personal use only Our 'buy, build, invest' strategy to sustained profitable growth 01 02 03 04 05 06 Acquire Hydrix Establish Hydrix Establish Hydrix Build Medical Group Revenue Group Services Ventures Medical Portfolio Growth Profitability Secret Sauce Value Capture Growth Catalyst Products Lic
Slide 5: Multiple large addressable markets
Multiple large addressable markets For personal use only Medical Group Priority • Cardiovascular disease (CVD) is the leading Innovations in Cardiac Health cause of death globally • Focus on >6B (2027) • 45% of Services client fee revenues, Ventures diagnostic & monitoring e.g., total artificial hea
Slide 6: Services: we create the innovation in breakthrough technologies
services We create the innovation in breakthrough technologies For personal use only Michael Trieu Peter Riddell Pauline Newman General Manager Global Head of Business Lead Program Manager Development Market focus • Safety critical systems e.g., artificial heart / VAD control systems • Growth sector
Slide 7: Ventures: we invest in the innovation in breakthrough technologies
ventures We invest in the innovation in breakthrough technologies For personal use only Gavin Coote Paul Kelly Alan Morris Executive Chairman Cardiac Product Strategy Global Marketing Director Ventures & Medical Portfolio Strategy • Early-stage, minority investment in clients developing world-first
Slide 8: Medical: we deliver the innovation in breakthrough technologies
medical We deliver the innovation in breakthrough technologies For personal use only Vickie Edwards James MacTaggart Deb White Director of Sales & Operations Sales and Clinical Manager Sales and Clinical Manager Market focus • Cardiovascular disease afflicts 14% of the population, is the leading cau
Slide 9: Business highlights and milestones past 12 months
HYDRIX Services HYDRIX Ventures Business highlights • Revenues $13.2m • Net Tangible Asset value & milestones (+34% fee revenues) increased 27% to $4.89m For personal use only past 12 months • EU & US revenues $7.25m (up 4x pcp FY21) • Capital raising revaluations, equity in-kind milestone achieveme
Slide 10: Goals for next 12 months
HYDRIX Services HYDRIX Ventures Goals for • >10% revenue growth • Avertix IPO next 12 months primarily from international For personal use only sales growth • Initial sales of Gyder in Australia, US FDA approval, capital raise Capitalising on significant opportunities created • More than double FY23
Slide 11: Key takeaways
Key takeaways For personal use only 1 Business in good hands, experienced leadership 2 Services profitable, strong revenue growth outlook 3 Ventures assets approaching liquidity events 4 Medical product sales coming, growth catalyst 5 Tracking to strategy, market value yet to catch up 10 |
Slide 12: Appendix
11 | For personal use only Appendix
Slide 13: Hydrix Limited – Board of Directors
Hydrix Limited – Board of Directors For personal use only Mr Gavin Coote Mr Paul Wright Mr Paul Lewis Ms Julie King Ms Joanne Bryant Ms Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Corporate Counsel Gavin has extensive execut
Slide 14: Hydrix – Senior Leadership
Hydrix – Senior Leadership For personal use only Paul Kelly Vickie Edwards Robert Brierly Alan Morris Gareth Evans General Manager Director Sales & Operations Group Director Group Director Group Hydrix Medical Hydrix Medical Human Resources Marketing Head of Finance Paul has 35+ years of Vickie has
Slide 15: Hydrix – Senior Leadership (cont'd)
Hydrix – Senior Leadership (cont’d) For personal use only Michael Trieu Peter Riddell Graeme Robertson Andrew Beal Peter Lewis, AM General Manager Director Business Develop. Project Management Engineering Manager EVP Business Development Hydrix Services Hydrix Services Director Hydrix Services Hydri
Slide 16: Corporate snapshot
Corporate snapshot – strong Top 20 support Sum of the parts valuation greater than the whole Major Shareholders Shares (m) % Capital Structure (as of 12 September 2023) For personal use only John W. King & related entities 27.3 10.8 Ticker HYD Paul Lewis & related entities 16.6 6.5 Share Price $0.02
Slide 17: Services: profitable, driving growth in International markets
services Hydrix Services (only): profitable, driving growth in International markets For personal use only * Hydrix Services EBITDA excludes COVID19 other income from government support programs and other non-cash and non-recurring expense items. Adjusted to include cash impact of occupancy costs 16
Slide 18: For personal use only
For personal use only Source: HYDRIX Audited Financial Accounts for the year ending 30 June 2023 17 |
Slide 19: Group cash flow improvement
For personal use only • Improvement in Group net cash from operating activities, cash use down 55% ($3.4m) to $2.7m • Reduction in cash used primarily attributable to Hydrix Services: improved cash operating profitability and changes in working capital • 2023 non-cash adjustments include expiration
Slide 20: Building a portfolio of AI technologies to better manage heart disease
medical Building a portfolio of AI technologies to better manage heart disease For personal use only Deals Distribution Large Addressable Market / Completed Geography Product Features Attractive Revenue Models AUS, NZ, SING A universal, alert-based platform for • >65k patients to monitor cardiac rem
Slide 21: The GUARDIAN: world's first real-time heart attack warning system
medical The GUARDIAN: the world’s first and only real-time heart attack warning system For personal use only Target problem Benefits offered Status (Hydrix) • Current standard of care --- patient must • The GUARDIAN, FDA approved, • Exclusive rights licensed to have symptoms, recognise the symptoms
Slide 22: Guardian regulatory approvals and reimbursement by country
medical Hydrix is actively working on regulatory approvals and reimbursement processes and other market development activities to commercialise the GUARDIAN in multiple Asia Pacific jurisdictions. For personal use only Country / Agency App. Date Status Notes USA / FDA n/a Approved Distributed in the
Slide 23: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Hydrix Limited expectations are based on reasonable assumptions, it can liability whatsoever for: (a) investment advice; (b) a (the “Company” or “Hydrix”). This presentation is being give no assurance that its goals will be achi
Slide 24: For more information, please visit www.hydrix.com
For personal use only For more information, please visit: www.hydrix.com